Literature DB >> 26609494

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Anita Midha1, Simon Dearden2, Rose McCormack2.   

Abstract

Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) histology (NSCLC/ADC). Robust data exist regarding the prevalence of EGFR mutations in Western and Asian patients with NSCLC/ADC, yet there is a lack of data for patients of other ethnicities. This review collated available data with the aim of creating a complete, global picture of EGFR mutation frequency in patients with NSCLC/ADC by ethnicity. Worldwide literature reporting EGFR mutation frequency in patients with NSCLC/ADC was reviewed, to create a map of the world populated with EGFR mutation frequency by country (a 'global EGFR mutMap'). A total of 151 worldwide studies (n=33162 patients with NSCLC/ADC, of which 9749 patients had EGFR mutation-positive NSCLC/ADC) were included. There was substantial variation in EGFR mutation frequency between studies, even when grouped by geographic region or individual country. As expected, the Asia-Pacific NSCLC/ADC subgroup had the highest EGFR mutation frequency (47% [5958/12819; 87 studies; range 20%-76%]) and the lowest EGFR mutation frequency occurred in the Oceania NSCLC/ADC subgroup (12% [69/570; 4 studies; range 7%-36%]); however, comparisons between regions were limited due to the varying sizes of the patient populations studied. In all regional (geographic) subgroups where data were available, EGFR mutation frequency in NSCLC/ADC was higher in women compared with men, and in never-compared with ever-smokers. This review provides the foundation for a global map of EGFR mutation frequency in patients with NSCLC/ADC. The substantial lack of data from several large geographic regions of the world, notably Africa, the Middle East, Central Asia, and Central and South America, highlights a potential lack of routine mutation testing and the need for further investigations in these regions.

Entities:  

Keywords:  Adenocarcinoma; EGFR mutation frequency; non-small-cell lung cancer

Year:  2015        PMID: 26609494      PMCID: PMC4633915     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  176 in total

1.  Detecting EGFR alterations in clinical specimens-pitfalls and necessities.

Authors:  Sofi Isaksson; Pär-Ola Bendahl; Annette Salomonsson; Mats Jönsson; Monica Haglund; Alexander Gaber; Karin Jirström; Per Jönsson; Ake Borg; Leif Johansson; Johan Staaf; Maria Planck
Journal:  Virchows Arch       Date:  2013-10-26       Impact factor: 4.064

2.  Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Vienna Ludovini; Fortunato Bianconi; Lorenza Pistola; Rita Chiari; Vincenzo Minotti; Renato Colella; Dario Giuffrida; Francesca Romana Tofanetti; Annamaria Siggillino; Antonella Flacco; Elisa Baldelli; Daniela Iacono; Maria Grazia Mameli; Antonio Cavaliere; Lucio Crinò
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

3.  Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population.

Authors:  Chong-Kin Liam; Hwong-Ruey Leow; Soon-Hin How; Yong-Kek Pang; Keong-Tiong Chua; Boon-Khaw Lim; Nai-Lang Lai; Yeh-Chunn Kuan; Jayalakshmi Pailoor; Pathmanathan Rajadurai
Journal:  Asian Pac J Cancer Prev       Date:  2014

4.  HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.

Authors:  Menghong Sun; Carmen Behrens; Lei Feng; Natalie Ozburn; Ximing Tang; Guosheng Yin; Ritsuko Komaki; Marileila Varella-Garcia; Waun Ki Hong; Kenneth D Aldape; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

5.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Ryoichi Onozato; Hiroyuki Kuwano; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

7.  Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.

Authors:  Chun-Chieh Wu; Hui-Yu Hsu; Hui-Ping Liu; John Wen-Cheng Chang; Ya-Ting Chen; Wen-Yu Hsieh; Jia-Juan Hsieh; Meng-Shu Hsieh; Yi-Rong Chen; Shiu-Feng Huang
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

8.  Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer.

Authors:  Miho Uhara; Kazuyuki Matsuda; Chiaki Taira; Yumiko Higuchi; Nubuo Okumura; Kazuyoshi Yamauchi
Journal:  Clin Chim Acta       Date:  2008-11-24       Impact factor: 3.786

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.

Authors:  Yuanyang Lai; Zhipei Zhang; Jianzhong Li; Dong Sun; Yong'an Zhou; Tao Jiang; Yong Han; Lijun Huang; Yifang Zhu; Xiaofei Li; Xiaolong Yan
Journal:  Int J Mol Sci       Date:  2013-12-17       Impact factor: 5.923

View more
  258 in total

1.  Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.

Authors:  J-I Lai; Y-C Lai; Y-C Chen; N-K Wang; J-N Pan; W-S Wang; S-C Chang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

Review 2.  Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer.

Authors:  Thomas M Churilla; Stephanie E Weiss
Journal:  Curr Oncol Rep       Date:  2018-05-07       Impact factor: 5.075

Review 3.  Lung cancer early detection and health disparities: the intersection of epigenetics and ethnicity.

Authors:  Lane Lerner; Robert Winn; Alicia Hulbert
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 4.  Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review.

Authors:  Jasmina Obradovic; Jovana Todosijevic; Vladimir Jurisic
Journal:  Mol Biol Rep       Date:  2021-05-10       Impact factor: 2.316

Review 5.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

6.  Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC-opportunities and obstacles.

Authors:  Brielle A Parris; Steven Leong; Henry Marshall; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  Ann Transl Med       Date:  2021-04

Review 7.  Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.

Authors:  D E Meyers; P M Bryan; S Banerji; D G Morris
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

8.  Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

Authors:  J Remon; D Isla; P Garrido; J de Castro; M Majem; N Viñolas; A Artal; E Carcereny; M R García-Campelo; P Lianes; M Provencio; O Juan; P Diz; R Blanco; R Lopez-Castro; I Maestu; C Vadell; E Felip
Journal:  Clin Transl Oncol       Date:  2017-06-28       Impact factor: 3.405

9.  Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations.

Authors:  Daniele Magnini; Leonello Fuso; Francesco Varone; Ettore D'Argento; Maurizio Martini; Antonietta Pecoriello; Vincenzo Di Noia; Damiano Arciuolo; Guido Fadda; Guido Rindi; Luca Richeldi
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

Review 10.  Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

Authors:  Linda O'Flaherty; Harriet Wikman; Klaus Pantel
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.